CalciMedica Shares Hit 52-Week Low After Ending Auxora Trial
By Chris Wack
CalciMedica shares were 82% lower, at 91 cents, after the company said it was discontinuing its Phase 2 clinical trial evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.
The stock hit its 52-week low of 82 cents earlier in the session, and is down 66% in the past 12 months.
The clinical-stage biopharmaceutical company said the decision follows a recommendation from the trial's independent data monitoring committee.
During a prescheduled interim data review, the committee identified a safety concern that, in its view, warrants reevaluation of the study design, particularly with respect to patient enrollment criteria.
The company said that there were no deaths in the trial that were assessed by investigators or CalciMedica as being related to study drug, with either Auxora or a placebo. No serious adverse events met the criteria for expedited reporting to the Food and Drug Administration.
Based on the committee's recommendation, the company has discontinued the trial and plans to perform a comprehensive review of the unblinded clinical data.
CalciMedica notified the FDA about the trial discontinuation and will work with investigators to ensure all patients currently enrolled in the trial complete the full 90-day follow-up.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 28, 2026 10:24 ET (15:24 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States